Literature DB >> 21627762

Human response to unintended intrathecal injection of botulinum toxin.

Ian Carroll1, Nancy Fischbein, Meredith Barad, Sean Mackey.   

Abstract

OBJECTIVE: Describe the first reported human intrathecal (IT) botulinum toxin injection.
DESIGN: Case report. SETTING AND PATIENTS: We report here the sequelae to an unintended IT injection of botulinum toxin type B (BTB) in a 60-year-old woman with chronic back pain.
RESULTS: Following the IT administration of BTB, the patient experienced the onset of symmetric ascending stocking distribution painful dysesthesias, which persisted for approximately 6 months before receding. Objective neurologic deficits were not appreciated, and analgesic effects were prominently absent.
CONCLUSIONS: Analgesic actions of botulinum toxins in animals and in humans have led to speculation that IT botulinum toxin might exert significant analgesic effects. The unusual and unexpected subsequent clinical course, neurologic sequelae, dysesthesias, and absence of analgesia suggest that botulinum toxin will not be a therapeutic modality to treat pain as proposed by those studying botulinum toxin in animal models. Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21627762     DOI: 10.1111/j.1526-4637.2011.01135.x

Source DB:  PubMed          Journal:  Pain Med        ISSN: 1526-2375            Impact factor:   3.750


  3 in total

1.  Botulinum toxin type A suppresses arterial vasoconstriction by regulating calcium sensitization and the endothelium-dependent endothelial nitric oxide synthase/soluble guanylyl cyclase/cyclic guanosine monophosphate pathway: An in vitro study.

Authors:  Liang Hu; Ya Feng; Wuchao Liu; Lingjing Jin; Zhiyu Nie
Journal:  Exp Biol Med (Maywood)       Date:  2019-09-23

Review 2.  Current and Future Issues in the Development of Spinal Agents for the Management of Pain.

Authors:  Tony L Yaksh; Casey J Fisher; Tyler M Hockman; Ashley J Wiese
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

Review 3.  Current status and future directions of botulinum neurotoxins for targeting pain processing.

Authors:  Sabine Pellett; Tony L Yaksh; Roshni Ramachandran
Journal:  Toxins (Basel)       Date:  2015-11-04       Impact factor: 4.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.